Novo Nordisk Medicare Price Fight: Court Ruling Explained
- A unanimous federal appeals court ruling upholds the program, allowing medicare to negotiate lower drug prices, a meaningful win for patients and the Biden administration.
- Court of Appeals for the District of Columbia Circuit delivered a decisive blow to Novo Nordisk, rejecting the pharmaceutical giant's challenge to the medicare drug price negotiation program...
- This ruling is especially impactful because Novo Nordisk argued that CMS's methodology unfairly disadvantaged its products.
“`html
Medicare Drug Price Negotiation Program Survives Novo Nordisk challenge
Table of Contents
A unanimous federal appeals court ruling upholds the program, allowing medicare to negotiate lower drug prices, a meaningful win for patients and the Biden administration.
What Happened: Court Rejects Novo Nordisk’s Appeal
On May 14, 2024, the U.S. Court of Appeals for the District of Columbia Circuit delivered a decisive blow to Novo Nordisk, rejecting the pharmaceutical giant’s challenge to the medicare drug price negotiation program established by the Inflation Reduction Act.The court affirmed that the Centers for Medicare & Medicaid Services (CMS) can group drugs with the same active ingredient together when selecting medications for price negotiation.
This ruling is especially impactful because Novo Nordisk argued that CMS’s methodology unfairly disadvantaged its products. The company contended that grouping drugs based on active ingredient,rather than specific formulations,violated statutory intent. The court disagreed, finding CMS’s interpretation reasonable and consistent with the law’s goals.
The Broader Legal Battles: A Losing Streak for Pharma
Novo Nordisk’s defeat is part of a larger trend. Pharmaceutical companies have faced consistent setbacks in their attempts to dismantle the Medicare negotiation program in court. Patients for Affordable Drugs reports at least 15 rulings against the industry as the law’s enactment in 2023. These challenges have centered on claims of violating the First, Fifth, and Eighth Amendments.
specifically, industry arguments have alleged that the program infringes on First Amendment speech protections, violates the Fifth Amendment’s due process requirements, and constitutes an excessive fine prohibited by the Eighth Amendment. Judges have consistently rejected these claims, emphasizing the government’s legitimate interest in lowering healthcare costs for seniors.
| Case Type | plaintiff | court Ruling | Date |
|---|---|---|---|
| First Amendment | Multiple Drugmakers | Dismissed | April 29, 2024 |
| Fifth Amendment | AstraZeneca | Dismissed | March 1, 2024 |
| Constitutional Challenge | PhRMA | dismissed | June 21, 2023 |
Understanding the Negotiation Framework
The Inflation Reduction Act allows medicare to negotiate prices for a limited number of high-expenditure drugs. The program phases in over several years. In 2023, CMS selected 10 drugs for initial negotiation. An additional 15 drugs were added for negotiation in 2024, and 20 new drugs will be selected annually thereafter, capping the number of drugs subject to negotiation at any given time.
Novo Nordisk’s lawsuit specifically targeted the CMS’s approach to drug selection. The company argued that grouping drugs with the same active ingredient unfairly limited competition and potentially excluded innovative formulations. The court, however, found this approach permissible under the law.
What This Means for Patients and the Industry
This ruling is a significant victory for the approximately 65 million Americans enrolled in medicare.Lower drug prices will translate into reduced out-of-pocket costs, particularly for those with chronic conditions requiring expensive medications. The Congressional Budget Office (CBO) estimates that the negotiation program will save Medicare over $100 billion
over the next decade.
For the